Role of the nicotinic cholingergic System in top down and bottom up control of attention

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00004529

Enrollment

200

Registered

2012-11-13

Start date

2011-05-02

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

healthy volunteers

Interventions

Group 1: NiQuitin 7mg (GSK patch) 1 x 50 min Group 2: placebo

Eligibility

Sex/Gender

All

Age

18 Years to 40 Years

Inclusion criteria

Inclusion criteria: MR compatible, healthy

Exclusion criteria

Exclusion criteria: neurological or psychiatric disease, metal in body, intake of drugs, smoker, left handed

Design outcomes

Primary

Measure	Time frame
Comparison nicotine-placebo. It is one measurement after acute application of the drug. Primary endpoint in fMRI is a significant change in BOLD activity in parietal cortex, on the behavioural side it is a significant change in reaction times in the experimental paradigm.	—

Secondary

Measure	Time frame
Comparison nicotine-placebo. It is one measurement after acute application of the drug. Secondary endpoint in fMRI is a significant change in BOLD activity in frontal and temporal cortex, on the behavioural side it is a significant change in accuracy and variability of reaction times in the experimental paradigm.	—

Countries

Germany

Contacts

Public ContactChristiane Thiel

Institit für Psychologie, Universität Oldenburg

christiane.thiel@uni-oldenburg.de0441-798-3641

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026